


PHARMACEUTICAL 2019

CELGENE CORP DE Rank 57 of 371





PHARMACEUTICAL 2019



CELGENE CORP DE Rank 57 of 371

The relative strengths and weaknesses of CELGENE CORP DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CELGENE CORP DE compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 271% points. The greatest weakness of CELGENE CORP DE is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 107% points.

The company's Economic Capital Ratio, given in the ranking table, is 73%, being 404% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	9,067,000
Cost of Goods Sold	587,000
Intangible Assets	24,216,000
Liabilities, Current	4,057,000
Liabilities, Non-Current	20,319,000
Other Assets	830,000
Other Compr. Net Income	233,000
Other Expenses	2,107,000
Other Liabilities	4,943,000
Other Net Income	382,000
Property and Equipment	1,367,000
Research and Development	5,673,000
Revenues	15,281,000
Selling, General and Administrative Expense	3,250,000

Output Variable	Value in 1000 USD
Assets	35,480,000
Liabilities	29,319,000
Expenses	11,617,000
Stockholders Equity	6,161,000
Net Income	4,046,000
Comprehensive Net Income	4,162,500
Economic Capital Ratio	73%